pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
17d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
17d
First U.S. bird flu death of the year after cattle exposure
stat
18d
‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts
stat
18d
Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft
biospace
18d
FDA peptide policy risks undermining drug development and patient safety
biospace
18d
Karyopharm, deep in debt, to sell itself in bankruptcy
biopharma dive
18d
Sun Pharma stops eye-care drug production at Indian plant amid quality issues
biospace
18d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
18d
STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries
stat
18d
UniQure gets review date and adcomm; Inovio's stock surges after approval
endpoints
18d
FDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’
fiercebiotech
18d
Keytruda biosimilars are coming — but they face an uphill battle
biopharma dive
18d
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
biospace
18d
FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
fda press
18d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
19d
Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned merger
fiercebiotech
19d
Breaking the silos: What effective scenario modeling looks like in 2026 and beyond
biopharma dive
19d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
19d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
19d
China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
fiercebiotech
19d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
19d
Recon: FDA approves generic lenacapavir intended for lower income countries; EMA to review Lundbeck's Deanxit for reported serio...
raps
21d
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
fda press
21d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
22d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
22d
Once undruggable, the Wnt/B-catenin pathway shows increasing promise
biospace
22d
When drug development gets personal
fiercebiotech
22d
Opinion: How Congress can fix expert advisory committees
stat
22d
The health care issues STAT reporters are watching in the midterms
stat
22d
Roche launches differential diagnosis test for mesothelioma
fiercebiotech
← prev
page 7 of 52
next →